The Effects of Caspofungin and Voriconazole in Experimental Candida Endophthalmitis

REFERENCES

• Rao N A, Hidayat A A. Endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared with aspergillosis. Am J Ophthalmol. 2001; 132: 244–251
   PubMed Web of Science ®Google Scholar
• McDonnell P J, McDonnell J M, Brown R H, Green W R. Ocular involvement in patients with fungal infections. Ophthalmology. 1985; 92: 706–709
   PubMed Web of Science ®Google Scholar
• Nguyen M H, Peacock J E, Jr., Morris A J, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996; 100: 617–623
   PubMed Web of Science ®Google Scholar
• Bodey G P, Mardani M, Hanna H A, et al. The epidemiology of Candida glabrata Candida albicans fungemia in immunocompromised patients with cancer. Am J Med. 2002; 112: 380–385
   PubMed Web of Science ®Google Scholar
• Donahue S P, Greven C M, Zuravleff J J, et al. Intraocular candidiasis in patients with candidemia. Ophthalmology. 1994; 101: 1302–1309
   PubMed Web of Science ®Google Scholar
• Feman S S, Nichols J C, Chung S M, Theobald T A. Endophthalmitis in patients with disseminated fungal disease. Trans Am Ophthalmol Soc. 2002; 100: 67–72
   PubMedGoogle Scholar
• Savani D V, Perfect J R, Cobo L M, Durack D T. Penteration of new azole compounds into eye and efficacy in experimental Candida endophthalmitis. Antimicrob. Agents Chemother. 1987; 31: 6–10
   PubMed Web of Science ®Google Scholar
• Axelrod A J, Peyman G A, Apple D J. Toxicity of intravitreal injection of amphotericin B. Am J Ophthalmol. 1973; 76: 578–583
   PubMed Web of Science ®Google Scholar
• Souri E N, Gren W R. Intravitreal amphotericin B toxicity. Am J Ophthalmol. 1974; 78: 77–81
   PubMed Web of Science ®Google Scholar
• Sabo J A, Abdel-Rahman S M. Voriconazole: a new triazole antifungal. Ann Pharmacother. 2000; 34: 1032–1043
   PubMed Web of Science ®Google Scholar
• Cornely O A, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses. 2002; 45: 56–60
   PubMed Web of Science ®Google Scholar
• Kartsonis N A, Nielsen J, Douglas C M. Caspofungin: the first in a new class of antifungal agents. Drug Resistance Updates. 2003; 6: 197–218
   PubMed Web of Science ®Google Scholar
• Apostolidis J, Bouzani M, Platsouka E, et al. Resolution of fungemia due to fusarium species in a patient with acute leukemia treated with caspofungin. Clin Infect Dis. 2003; 36: 1349–1350
   PubMed Web of Science ®Google Scholar
• Garbino J, Ondrusova A, Baligvo E, et al. Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole. Scand J Infect Dis. 2002; 34: 701–703
   PubMed Web of Science ®Google Scholar
• Sarria J C, Bradley J C, Habash R, et al. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis. 2005; 40: 46–48
   PubMedGoogle Scholar
• Peyman G A, Pague J T, Meisels H I, Bennet T O. Postoperative endophthalmitis: a comparison of methods of treatment and prophylaxis with gentamisin. Ophthalmic Surg. 1975; 6: 45–55
   PubMedGoogle Scholar
• National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard, Second edition. UCCLS, Wayne, PA 2002, NCCLS document M27-A2
   Google Scholar
• Pfaller M A, Messer S A, Linda Boyken L, et al. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol. 2003; 41: 5729–5731
   PubMed Web of Science ®Google Scholar
• O'Day D M, Head W S, Robinson R D, et al. Intraocular penetration of systemically administered antifungal. Curr Eye Res. 1985; 4: 131–134
   PubMed Web of Science ®Google Scholar
• O'Day D M, Foulds G, Williams T E, et al. Ocular uptake of fluconazole following oral administration. Arch Ophthalmol. 1990; 108: 1006–1008
   PubMed Web of Science ®Google Scholar
• Marangon F B, Miller D, Giaconi J A, Alfonso E C. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol. 2004; 137: 820–825
   PubMed Web of Science ®Google Scholar
• Louie A, Liu W, Miller D A, et al. Efficacies of high-dose fluconazole plus amphotericin B and high-dose plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monoterapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob Agents Chemother 1999; 43: 2831–2840
   PubMed Web of Science ®Google Scholar
• Hariprasad S M, Mieler W F, Holz E R, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004; 122: 42–47
   PubMed Web of Science ®Google Scholar
• Gao H, Pennesi M, Shah K, et al. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch Ophthalmol. 2004; 122: 1687–1692
   PubMedGoogle Scholar
• Reis A, Sundmacher R, Tintelnot K, et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol. 2000; 84: 932–933
   PubMed Web of Science ®Google Scholar
• Sarria J C, Bradley J C, Habash R, et al. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis. 2005; 40: 46–48
   PubMedGoogle Scholar
• Breit S M, Hariprasad S M, Mieler W F, et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol. 2005; 139: 135–140
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Spreghini E, Baldassarril I, et al. Sequential therapy with caspofungin and fluconazole for Candida albicans infection. Antimicrob Agents Chemother. 2004; 48: 4056–4058
   Google Scholar
• Schulman J A, Peyman G A, Dietlein J, Fiscella R. Ocular toxicity of experimental intravitreal itraconazole. Int Ophthalmol. 1991; 15: 21–24
   PubMed Web of Science ®Google Scholar
• Schulman J A, Peyman G, Fiscella R, et al. Toxicity of intravitreal injection of fluconazole in the rabbit. Can J Ophthalmol. 1987; 22: 304–306
   PubMed Web of Science ®Google Scholar
• Filler S G, Crislip M A, Mayer C L, Edwards J E, Jr. Comparison of fluconazole and amphotericin B for treatment of disseminated Candidiasis and endophthalmitis in rabbits. Antimicrob Agents Chemother. 1991; 35: 288–292
   PubMed Web of Science ®Google Scholar
• Gupta S K, Dhingra N, Velpandian T, et al. Efficacy of fluconazole and liposome entrapped fluconazole for Candida albicans induced experimental mycotic endophthalmitis in rabbit eyes. Acta Ophthalmol Scand. 2000; 78: 448–450
   PubMedGoogle Scholar